title: [Induction of myocardial neoangiogenesis by human growth factors. A new therapeutic approach in coronary heart disease].
abstract: Currently available approaches for treating human coronary heart disease aim to relieve symptoms and the risk of myocardial infarction either by reducing myocardial oxygen demand, preventing further disease progression, restoring coronary blood flow pharmacologically or mechanically, or bypassing the stenotic lesions and obstructed coronary artery segments. Gene therapy, especially using angiogenic growth factors, has emerged recently as a potential new treatment for cardiovascular disease. Following extensive experimental research on angiogenic growth factors, the first clinical studies on patients with coronary heart disease and peripheral vascular lesions have been performed. The polypeptides fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) appear to be particularly effective in initiating neovascularization (neoangiogenesis) in hypoxic or ischemic tissues. The first clinical study on patients with coronary heart disease treated by local intramyocardial injection of FGF-1 showed a 3-fold increase of capillary density mediated by the growth factor. Also, angiogenic growth factor injection intramyocardially as sole therapy for end-stage coronary disease showed an improvement of myocardial perfusion in the target areas as well as a reduction of symptoms and an increase in working capacity. Angiogenic therapy of the human myocardium introduces a new modality of treatment for coronary heart disease in terms of regulation of blood vessel growth. Beyond drug therapy, angioplasty and bypass surgery, this new approach may evolve into a fourth principle of treatment of atherosclerotic cardiovascular disease.
authors.affiliation: Klinik für Thorax-, Herz- und Gefässchirurgie Fulda. heart.stegmann@klinikum-fulda.de
authors.forename: T J
authors.initials: TJ
authors.lastname: Stegmann
authors.forename: T
authors.initials: T
authors.lastname: Hoppert
authors.forename: A
authors.initials: A
authors.lastname: Schneider
authors.forename: S
authors.initials: S
authors.lastname: Gemeinhardt
authors.forename: M
authors.initials: M
authors.lastname: Köcher
authors.forename: R
authors.initials: R
authors.lastname: Ibing
authors.forename: G
authors.initials: G
authors.lastname: Strupp
mesh_terms: D043925:Angiogenesis Inducing Agents / Q000627:therapeutic use*; D000818:Animals; D003326:Coronary Circulation / Q000187:drug effects*; D003327:Coronary Disease / Q000188:drug therapy*; D016228:Endothelial Growth Factors / Q000627:therapeutic use*; D005346:Fibroblast Growth Factors / Q000627:therapeutic use*; D006801:Humans; D008222:Lymphokines / Q000627:therapeutic use*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D043925:Angiogenesis Inducing Agents; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D005346:Fibroblast Growth Factors